Conference Coverage

DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening

Publish date: August 27, 2022

 

AT ESC CONGRESS 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Does DTC heart drug advertising discourage lifestyle changes?
MDedge Family Medicine
Cholesterol levels lowering in U.S., but disparities emerge
MDedge Family Medicine
How much weight does my patient need to lose?
MDedge Family Medicine
Barcelona beckons for first hybrid ESC Congress
MDedge Family Medicine
‘Conservative’ USPSTF primary prevention statin guidance finalized
MDedge Family Medicine
NSAIDs linked to heart failure risk in diabetes
MDedge Family Medicine
Early menopause linked with increased risk of heart problems
MDedge Family Medicine
Congressman’s wife died after taking herbal remedy marketed for diabetes and weight loss
MDedge Family Medicine
Secondary CV prevention benefit from polypill promises global health benefit
MDedge Family Medicine
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
MDedge Family Medicine